Silence Therapeutics Plc - ADR

NASDAQ:SLN   12:53:02 PM EDT
33.50
+5.19 (+18.32%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)998.27M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$41.49 Million
Adjusted EPS$0.85
See more estimates
10-Day MA$28.52
50-Day MA$25.44
200-Day MAN/A
See more pivots

Silence Therapeutics Plc - ADR Stock, NASDAQ:SLN

72 Hammersmith Road, London, Greater London W14 8TH
Phone: +44.20.3457.6900
Number of Employees:

Description

Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. It develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.